Indian pharmaceutical stocks came under severe pressure following US President Donald Trump's announcement of a phased tariff plan for imported generic medicines. The Nifty Pharma index declined 1.3% on Wednesday, with Dr Reddy's Laboratories declining 1.9% and Cipla losing 1.2% as investors assessed the potential impact on Indian exporters. The selling pressure was more pronounced than previous sessions, with Lupin leading losses at 4.3%, followed by Piramal Pharma, Ajanta Pharma, Aurobindo Pharma, Alembic Pharmaceuticals, and Granules (India) which declined between 2.5% and 4.2%. Other major losers included Sun Pharma, the index heavyweight, declining 1.19%, while Divi's Laboratories and Abbott India posted gains of 0.68% and 0.12% respectively. The India VIX rose 3.8%, reflecting heightened market volatility amid the tariff announcement. Trading volumes stood at 199.41 lakh shares with a traded value of ₹2,230.73 crore, indicating significant investor participation in the sector-wide decline.
US President Donald Trump announced a phased tariff plan for imported generic medicines, providing a two-year reprieve before implementing steep duties. Taking to Truth Social, Trump outlined the policy as follows: "Effective August 1, 2026, all Generic Drugs being brought into the United States will continue to have a 'Tariff of zero per cent' for a two-year period of time, after which the tariff will be raised to 100% for a one-year period of time and 200% thereafter." The timeline shows tariffs rising to 100% after two years, remaining at that level for one year, and increasing to 200% thereafter. This would mean a 100% tariff from August 1, 2028, and a 200% levy from August 1, 2029. The phased tariff plan is intended to encourage pharmaceutical companies to establish manufacturing plants and related infrastructure in the US during the transition period. Companies that do not localise production would eventually face higher import duties under the administration's broader "America First" manufacturing agenda. The policy does not alter the administration's approach toward patented, branded and innovative medicines, focusing specifically on generic pharmaceutical production. India exports approximately $8-9 billion worth of pharmaceutical products to the US annually, the bulk of which are generics.
Pharma stocks traded lower on Friday, 24 July, after President Trump announced a phased tariff plan for imported generic medicines, raising concerns over the outlook for Indian drug exporters. Abbott India shares were the biggest laggards, falling 3.69% on the BSE, prompting fears over the future of American production and long-term impacts on stocks. Akums Drugs & Pharmaceuticals shares also witnessed notable selling pressure, slipping 2.06%, while Acutaas Chemicals shares declined 1.99%, and Aarti Drugs shares fell 1.76%. Shares of Alembic dropped 1.61%, Ajanta Pharma lost 1.43%, and Artemis Medicare Services declined 1.32%, reflecting weakness across the broader pharma pack. The US is the largest overseas market for Indian pharmaceutical companies, with IQVIA data showing that Indian drugmakers account for nearly 47% of the US generic medicines market. According to PL Capital, the announcement was largely unexpected and significant uncertainty remains around how the tariff policy will eventually be implemented.
Indian pharmaceutical stocks have reacted cautiously to Trump's proposed tariffs rather than witnessing a sector-wide sell-off, with Dr Reddy's Laboratories falling 4.56% over the past week while other major players like Zydus Lifesciences (-3.79%), Cipla (-2.25%), Glenmark Pharma (-1.34%), and Aurobindo Pharma (-0.43%) also declined. According to CNBC TV18, this muted response reflects four key factors: the two-year implementation window provides companies time to assess options, moving generic manufacturing to the US is economically difficult due to cost differentials, Indian drugmakers already have significant US manufacturing footprint, and the entire tariff burden may not be absorbed by pharmaceutical companies. Anuj Sethi, Senior Director at Crisil Ratings, noted that "The two-year implementation window provides companies an opportunity to adapt their supply chains." The industry is also waiting for greater clarity on the final tariff structure and outcome of India-US trade negotiations. Priyanka Chigurupati, Executive Director of Granules India, emphasized that moving large-scale generic production to the US would be "close to being impossible at this point purely because of the cost differential," with manufacturing costs potentially rising by 20% to 25%.
Sudeep Shah, Head of Technical and Derivatives Research at SBI Securities, said the Nifty Pharma Index has corrected by around 2% from its recent high of 26,136, recorded on 16 July, following the announcement of proposed US tariffs on imported generic medicines, effective from August 2028. He noted that the index appears to have largely priced in the news, witnessing buying interest at lower levels although the rebound lacked strong momentum. Technically, the index is trading marginally below an upward-sloping trendline connecting the swing lows of 21,150 (2 April) and 24,035 (17 June), and has also slipped slightly below its 20-day exponential moving average. The Relative Strength Index (RSI) has fallen below the 60 mark, indicating a temporary loss of momentum. However, Shah believes it is premature to conclude that the current correction marks the beginning of a broader trend reversal. According to him, the 25,300-25,250 zone is the immediate support for the Nifty Pharma Index, and as long as it holds above this level, the broader bullish structure is likely to remain intact. On the upside, he identified the 25,700-25,750 zone as the immediate resistance, adding that a decisive breakout above this range could signal a resumption of the prevailing uptrend.
